IL2 and COVID-19: Therefore, the replacement cytokine-based therapy, with IL-2 stimulating lymphocyte proliferative activity, seems particularly appropriate in patients with COVID-19 during the shift from the hyper-inflammatory to the hypo-inflammatory phase.